Kenya to roll out game-changing HIV drug in March

Healthcare Update: Rollout of New HIV-Prevention Drug in Kenya

Kenya is set to commence the distribution of a new HIV-prevention drug, Lenacapavir, in March. This medication, developed by Gilead Sciences, offers significant protection against HIV transmission with just two injections per year.

Lenacapavir reduces the risk of HIV transmission by over 99.9 percent. The initial supply of 21,000 doses was received on Tuesday through an agreement with the Global Fund.

The first phase of the rollout will begin in early March, targeting 15 counties. Health Minister Aden Duale announced that an additional 12,000 doses are expected by April.

This initiative occurs as African nations face potential changes in foreign aid priorities. Eastern and southern Africa represent 52 percent of the global population living with HIV, which totals 40.8 million people. The United States has committed an additional 25,000 doses to Kenya, where the HIV prevalence rate is 3.7 percent.

In December, Kenya entered into a $2.5 billion health agreement with the United States. Under this partnership, the US will provide $1.6 billion over five years, while Kenya will contribute $850 million, with a plan for increased local responsibility over time. However, this agreement is currently under judicial review due to allegations of constitutional breaches by a Kenyan senator.

Based on reporting by Africanews.